8/10/2020  10:24:46 AM Chg. -0.21 Volume Bid10:25:40 AM Ask10:27:22 AM Market Capitalization Dividend Y. P/E Ratio
38.29EUR -0.55% 1,230
Turnover: 47,019
38.22Bid Size: 86 38.35Ask Size: 102 4.01 bill.EUR 3.90% 26.92

Business description

Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group. Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo.
 

Management board & Supervisory board

CEO
Timo Lappalainen
Management board
Jari Karlson, Liisa Hurme, Olli Huotari, Outi Vaarala, Satu Ahomäki, Virve Laitinen
Supervisory board
Mikael Silvennoinen, Ari Lehtoranta, Eija Ronkainen, Hilpi Rautelin, Kari Jussi Aho, Pia Kalsta, Timo Maasilta
 

Company data

Name: Orion Corporation
Address: Orionintie 1A,FI-02200 Espoo
Phone: +358-10-4261
Fax: -
E-mail: -
Internet: is.gd/3PivOU
Industry: Healthcare
Sector: Healthcare Providers
Sub sector: Healthcare Providers
End of financial year: 12/31
Free Float: 97.47%
IPO date: -

Investor relations

Name: Jari Karlson
IR phone: +358-10-426-2883
IR Fax: -
IR e-mail: -

Company calendar

CW 43 | 10/21/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
97.47%
Ilmarinen Mutual Pension Insurance Company
 
2.53%